{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:04:03Z","timestamp":1780509843233,"version":"3.54.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-10-INBS-04"],"award-info":[{"award-number":["ANR-10-INBS-04"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-10-LABX-53\\u201301"],"award-info":[{"award-number":["ANR-10-LABX-53\\u201301"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004100","name":"Labex","doi-asserted-by":"publisher","award":["ANR-22-PEBI-0009"],"award-info":[{"award-number":["ANR-22-PEBI-0009"]}],"id":[{"id":"10.13039\/501100004100","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008222","name":"Universit\u00e9 de Montpellier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008222","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA20113"],"award-info":[{"award-number":["CA20113"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009469","name":"Conseil R\u00e9gional du Centre-Val de Loire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118775","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:11:25Z","timestamp":1763640685000},"page":"118775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Anti-cathepsin D antibody-drug conjugates for the targeted delivery of monomethyl auristatin F and E elicit potent anticancer activity in breast cancer"],"prefix":"10.1016","volume":"193","author":[{"given":"Diane","family":"Nishimwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Guillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Mallavialle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Huvelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay B.","family":"Alcaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Garapon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Garambois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanane","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Boissi\u00e8re-Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Berestjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jarlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Turtoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Denevault-Sabourin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Chard\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Laurent-Matha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Liaudet-Coopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118775_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2025.118775_bib2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrclinonc.2013.124","article-title":"Luminal breast cancer: from biology to treatment","volume":"10","author":"Ignatiadis","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118775_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103691","article-title":"Real-world treatment patterns and outcomes in patients with HR+\/HER2- metastatic breast cancer treated with chemotherapy in the United States","volume":"9","author":"Tolaney","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2025.118775_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103695","article-title":"Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?","volume":"9","author":"Zagami","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2025.118775_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104634","article-title":"Beyond failure of endocrine-based therapies in HR+\/HER2 negative advanced breast cancer: What before chemotherapy? A glimpse into the future","volume":"208","author":"Torrisi","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2025.118775_bib6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118775_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody-drug conjugate landscape","volume":"23","author":"Flynn","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118775_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100074","article-title":"The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer","volume":"6","author":"Delgado","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2025.118775_bib9","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-20-4557","article-title":"FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2025.118775_bib10","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.22.02447","article-title":"US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer","volume":"41","author":"Narayan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118775_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2025.118775_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","author":"Zippelius","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118775_bib13","doi-asserted-by":"crossref","first-page":"2443538","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.biopha.2025.118775_bib14","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab Vedotin: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2025.118775_bib15","first-page":"6008","article-title":"Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer","volume":"49","author":"Thorpe","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118775_bib16","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(89)91487-6","article-title":"Cathepsin D: an independent prognostic factor for metastasis of breast cancer","volume":"2","author":"Spyratos","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118775_bib17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/bjc.1997.442","article-title":"Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis","volume":"76","author":"Ferrandina","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118775_bib18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.bjc.6690048","article-title":"Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients","volume":"79","author":"Foekens","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118775_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920927838","article-title":"Prognostic role of high cathepsin D expression in breast cancer: a systematic review and meta-analysis","volume":"12","author":"Kang","year":"2020","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.biopha.2025.118775_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10549-024-07293-y","article-title":"Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value","volume":"206","author":"Alhudiri","year":"2024","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.biopha.2025.118775_bib21","article-title":"A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index","volume":"8","author":"Huang","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.biopha.2025.118775_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051244","article-title":"Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival","volume":"12","author":"Mansouri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2025.118775_bib23","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1210\/endo-118-4-1537","article-title":"Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein","volume":"118","author":"Vignon","year":"1986","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2025.118775_bib24","first-page":"3904","article-title":"Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells","volume":"49","author":"Capony","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118775_bib25","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1038\/sj.onc.1205745","article-title":"Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis","volume":"21","author":"Berchem","year":"2002","journal-title":"Oncogene"},{"issue":"Pt 3","key":"10.1016\/j.biopha.2025.118775_bib26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1042\/bj3030775","article-title":"Mitogenic function of human procathepsin D: the role of the propeptide","volume":"303","author":"Fusek","year":"1994","journal-title":"Biochem J."},{"key":"10.1016\/j.biopha.2025.118775_bib27","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1038\/sj.onc.1204843","article-title":"A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells","volume":"20","author":"Glondu","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118775_bib28","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1038\/sj.onc.1205657","article-title":"Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells","volume":"21","author":"Glondu","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118775_bib29","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1038\/s41467-020-18935-2","article-title":"Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling","volume":"11","author":"Ketterer","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118775_bib30","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1242\/jcs.070938","article-title":"Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth","volume":"123","author":"Beaujouin","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.biopha.2025.118775_bib31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1083\/jcb.200403078","article-title":"Catalytically inactive human cathepsin D triggers fibroblast invasive growth","volume":"168","author":"Laurent-Matha","year":"2005","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118775_bib32","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1158\/0008-5472.CAN-07-6276","article-title":"Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis","volume":"68","author":"Hu","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118775_bib33","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0002-9440(10)63914-4","article-title":"Cathepsin D specifically cleaves the chemokines macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, and SLC that are expressed in human breast cancer","volume":"162","author":"Wolf","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2025.118775_bib34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s12276-024-01163-9","article-title":"Cathepsin D promotes polarization of tumor-associated macrophages and metastasis through TGFBI-CCL20 signaling","volume":"56","author":"Lee","year":"2024","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.biopha.2025.118775_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.02.008","article-title":"Cathepsin D--many functions of one aspartic protease","volume":"68","author":"Benes","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2025.118775_bib36","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.4049\/jimmunol.176.11.6512","article-title":"Function of liver activation-regulated chemokine\/CC chemokine ligand 20 is differently affected by cathepsin B and cathepsin D processing","volume":"176","author":"Hasan","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2025.118775_bib37","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.7150\/thno.58254","article-title":"A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment","volume":"11","author":"Alcaraz","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2025.118775_bib38","doi-asserted-by":"crossref","DOI":"10.1096\/fj.12-205229","article-title":"Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment","author":"Laurent-Matha","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2025.118775_bib39","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3892\/ijo.2013.2095","article-title":"Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment","volume":"43","author":"Maynadier","year":"2013","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.biopha.2025.118775_bib40","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.biochi.2010.05.009","article-title":"Pathophysiological functions of cathepsin D: Targeting its catalytic activity versus its protein binding activity?","volume":"92","author":"Masson","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.biopha.2025.118775_bib41","doi-asserted-by":"crossref","DOI":"10.4172\/0974-8369.1000206","article-title":"Two Faces of Cathepsin D: Physiological Guardian Angel and Pathological Demon","volume":"6","author":"Khalkhali-Ellis","year":"2014","journal-title":"Biol. Med (Aligarh)"},{"key":"10.1016\/j.biopha.2025.118775_bib42","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/(SICI)1097-0215(19971104)73:3<403::AID-IJC15>3.0.CO;2-D","article-title":"Analysis of the interaction of procathepsin D activation peptide with breast cancer cells","volume":"73","author":"Vetvicka","year":"1997","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.biopha.2025.118775_bib43","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1038\/onc.2011.501","article-title":"Cathepsin D is partly endocytosed by the LRP1 receptor and inhibits LRP1-regulated intramembrane proteolysis","volume":"31","author":"Derocq","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118775_bib44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbamcr.2017.10.005","article-title":"Cathepsin D non-proteolytically induces proliferation and migration in human omental microvascular endothelial cells via activation of the ERK1\/2 and PI3K\/AKT pathways","volume":"1865","author":"Pranjol","year":"2018","journal-title":"Biochim Biophys. Acta Mol. Cell Res"},{"issue":"Pt 17","key":"10.1016\/j.biopha.2025.118775_bib45","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1242\/jcs.111.17.2539","article-title":"Endocytosis of pro-cathepsin D into breast cancer cells is mostly independent of mannose-6-phosphate receptors","volume":"111","author":"Laurent-Matha","year":"1998","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.biopha.2025.118775_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40425-019-0498-z","article-title":"Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies","volume":"7","author":"Ashraf","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118775_bib47","article-title":"Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer","author":"David","year":"2023","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118775_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007135","article-title":"A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer","volume":"12","author":"Desroys du Roure","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118775_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009548","article-title":"Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy","volume":"13","author":"Desroys du Roure","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118775_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/bph.17437","article-title":"Cathepsins: Novel opportunities for antibody therapeutics in cancer","author":"David","year":"2025","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118775_bib51","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1038\/s41467-022-31601-z","article-title":"Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy","volume":"13","author":"Hingorani","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118775_bib52","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bc0502917","article-title":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","volume":"17","author":"Doronina","year":"2006","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.biopha.2025.118775_bib53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF01518520","article-title":"Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies","volume":"37","author":"Lewis","year":"1993","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2025.118775_bib54","first-page":"3229","article-title":"MCF7\/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780","volume":"53","author":"Brunner","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118775_bib55","first-page":"3709","article-title":"Characterization and properties of two monoclonal antibodies specific for the Mr 52,000 precursor of cathepsin D in human breast cancer cells","volume":"48","author":"Freiss","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118775_bib56","first-page":"709","article-title":"Characterization of monoclonal antibodies to the estrogen-regulated Mr 52,000 glycoprotein and their use in MCF7 cells","volume":"45","author":"Garcia","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118775_bib57","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1021\/acs.bioconjchem.8b00668","article-title":"Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro","volume":"29","author":"Aubrey","year":"2018","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.biopha.2025.118775_bib58","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/jnci\/51.5.1409","article-title":"A human cell line from a pleural effusion derived from a breast carcinoma","volume":"51","author":"Soule","year":"1973","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2025.118775_bib59","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1021\/pr200212r","article-title":"Novel comprehensive approach for accessible biomarker identification and absolute quantification from precious human tissues","volume":"10","author":"Turtoi","year":"2011","journal-title":"J. Proteome Res"},{"key":"10.1016\/j.biopha.2025.118775_bib60","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.7150\/thno.90627","article-title":"Cancer-associated fibroblast spatial heterogeneity and EMILIN1 expression in the tumor microenvironment modulate TGF-beta activity and CD8(+) T-cell infiltration in breast cancer","volume":"14","author":"Honda","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2025.118775_bib61","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118775_bib62","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajpath.2010.08.004","article-title":"Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapies","volume":"178","author":"Turtoi","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2025.118775_bib63","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/1097-0142(19940601)73:11<2771::AID-CNCR2820731120>3.0.CO;2-K","article-title":"Detection of HER-2\/neu oncogene amplification in flow cytometry-sorted breast ductal cells by competitive polymerase chain reaction","volume":"73","author":"Li","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2025.118775_bib64","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1039\/C7OB02780J","article-title":"Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates","volume":"16","author":"Bryden","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.biopha.2025.118775_bib65","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.biopha.2025.118775_bib66","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118775_bib67","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118775_bib68","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1021\/bc500148x","article-title":"Bridging disulfides for stable and defined antibody drug conjugates","volume":"25","author":"Badescu","year":"2014","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.biopha.2025.118775_bib69","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1039\/C4OB01550A","article-title":"Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging","volume":"12","author":"Schumacher","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.biopha.2025.118775_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114063","article-title":"Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate","volume":"229","author":"Mohamed Amar","year":"2022","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2025.118775_bib71","article-title":"In Vitro Characterization and Stability Profiles of Antibody-Fluorophore Conjugates Derived from Interchain Cysteine Cross-Linking or Lysine Bioconjugation","volume":"12","author":"Martin","year":"2019","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.biopha.2025.118775_bib72","doi-asserted-by":"crossref","first-page":"19122","DOI":"10.1021\/acs.jmedchem.5c01184","article-title":"Development of Optimized Exatecan-Based Immunoconjugates with Potent Antitumor Efficacy in HER2-Positive Breast Cancer","volume":"68","author":"Auvert","year":"2025","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2025.118775_bib73","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jconrel.2024.01.012","article-title":"Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer","volume":"366","author":"Douez","year":"2024","journal-title":"J. Control Release"},{"key":"10.1016\/j.biopha.2025.118775_bib74","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"E.G.C.E.a. clinicalguidelines@esmo.org, ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2025.118775_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01833333","article-title":"Interactions of pro-cathepsin D and IGF-II on the mannose-6-phosphate\/IGF-II receptor","volume":"22","author":"Vignon","year":"1992","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.biopha.2025.118775_bib76","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","article-title":"Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing","volume":"66","author":"Erickson","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118775_bib77","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/0008-5472.CAN-05-3973","article-title":"Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen","volume":"66","author":"Kovtun","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118775_bib78","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejmech.2017.08.049","article-title":"Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy","volume":"142","author":"Joubert","year":"2017","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2025.118775_bib79","first-page":"13","article-title":"Antibody-Drug Conjugates: The Last Decade","author":"Joubert","year":"2020","journal-title":"Pharm. (Basel"},{"key":"10.1016\/j.biopha.2025.118775_bib80","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118775_bib81","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1021\/bc800289a","article-title":"Novel peptide linkers for highly potent antibody-auristatin conjugate","volume":"19","author":"Doronina","year":"2008","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.biopha.2025.118775_bib82","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biopha.2025.118775_bib83","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/ijc.30569","article-title":"Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix","volume":"140","author":"Gebleux","year":"2017","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.biopha.2025.118775_bib84","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdw678","article-title":"Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer","volume":"28","author":"M.R","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2025.118775_bib85","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1535-7163.MCT-18-0252","article-title":"RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt\/g4-MMAE","volume":"17","author":"Suthe","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118775_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115489","article-title":"Development of a MMAE-based antibody-drug conjugate targeting B7-H3 for glioblastoma","volume":"257","author":"Mao","year":"2023","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2025.118775_bib87","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/1061186X.2018.1450413","article-title":"Preparation and anti-cancer evaluation of promiximab-MMAE, an anti-CD56 antibody drug conjugate, in small cell lung cancer cell line xenograft models","volume":"26","author":"Yu","year":"2018","journal-title":"J. Drug Target"},{"key":"10.1016\/j.biopha.2025.118775_bib88","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2018.12.018","article-title":"Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates","volume":"294","author":"Giansanti","year":"2019","journal-title":"J. Control Release"},{"key":"10.1016\/j.biopha.2025.118775_bib89","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/ncb3015","article-title":"The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis","volume":"16","author":"McAllister","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118775_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108022","article-title":"Therapeutic antibodies - natural and pathological barriers and strategies to overcome them","volume":"233","author":"Al Ojaimi","year":"2022","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2025.118775_bib91","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1158\/2767-9764.CRC-24-0248","article-title":"Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody-Drug Conjugate Targeting Fibroblast Activation Protein","volume":"4","author":"Gallant","year":"2024","journal-title":"Cancer Res Commun."},{"key":"10.1016\/j.biopha.2025.118775_bib92","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","article-title":"LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates","volume":"78","author":"Purcell","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118775_bib93","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1172\/JCI120481","article-title":"Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release","volume":"128","author":"Szot","year":"2018","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2025.118775_bib94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/acs.bioconjchem.4c00503","article-title":"Delivery of Monomethyl Auristatin F to the Tumor Microenvironment with Noninternalizing Fibroblast Activation Protein-Cleavable Small Molecule-Drug Conjugates Elicits Potent In Vivo Anticancer Activity","volume":"36","author":"Bocci","year":"2025","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.biopha.2025.118775_bib95","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jconrel.2024.02.014","article-title":"In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment","volume":"367","author":"Bocci","year":"2024","journal-title":"J. Control Release"},{"key":"10.1016\/j.biopha.2025.118775_bib96","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CMR.0b013e32833279f2","article-title":"B16 melanoma secretomes and in vitro invasiveness: syntenin as an invasion modulator","volume":"20","author":"Rondepierre","year":"2010","journal-title":"Melanoma Res"},{"key":"10.1016\/j.biopha.2025.118775_bib97","first-page":"4070","article-title":"Invasive properties of murine squamous carcinoma cells: secretion of matrix-degrading cathepsins is attributable to a deficiency in the mannose 6-phosphate\/insulin-like growth factor II receptor","volume":"60","author":"Lorenzo","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118775_bib98","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1074\/mcp.M500178-MCP200","article-title":"Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach","volume":"5","author":"Gronborg","year":"2006","journal-title":"Mol. Cell Proteom."},{"key":"10.1016\/j.biopha.2025.118775_bib99","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000024520","article-title":"Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors","volume":"18","author":"Tews","year":"1998","journal-title":"Invasion Metastas.."},{"key":"10.1016\/j.biopha.2025.118775_bib100","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/437143","article-title":"Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes","volume":"2010","author":"Srisomsap","year":"2010","journal-title":"J. Biomed. Biotechnol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:15:46Z","timestamp":1777014946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225009692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":100,"alternative-id":["S0753332225009692"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118775","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-cathepsin D antibody-drug conjugates for the targeted delivery of monomethyl auristatin F and E elicit potent anticancer activity in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118775"}}